Acquiring Company
Shionogi & Ltd
Acquired Company
IntraBio Inc
Osaka
AustinBiotechnologyHealth CarePharmaceuticalBiotechnologyDescription
Shionogi & Co. has acquired IntraBio for $2 billion to enhance its rare disease strategy. The acquisition includes IntraBio's drug Aqneursa, which has FDA approval for specific rare neurological conditions. Shionogi aims to strengthen its pipeline and commitment to rare diseases with this deal. Regulatory reviews are still pending for the acquisition.
Fundz sees it the moment Shionogi & Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired IntraBio Inc?
IntraBio Inc was acquired by Shionogi & Ltd, based in Osaka. The deal was reported on October 5, 2026. Shionogi & Co., Ltd. is a Japanese pharmaceutical company that focuses on the discovery and development of innovative medicines. Shionogi & Ltd is publicly traded (SGIOF) and operates in Biotechnology.
When did Shionogi & Ltd acquire IntraBio Inc?
Shionogi & Ltd's acquisition of IntraBio Inc was reported on October 5, 2026. Shionogi & Co. has acquired IntraBio for $2 billion to enhance its rare disease strategy. The acquisition includes IntraBio's drug Aqneursa, which has FDA approval for specific rare neurological conditions. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does IntraBio Inc do?
IntraBio Inc is a private pharmaceutical company located in London, United Kingdom, focusing on drug development and commercialization related to common and rare neurodegenerative diseases, as well as ageing and healthspan. It is privately held, operating in Biotechnology, and is based in Austin.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.